Vivelle-Dot Gains Despite Flagging Hormone Therapy Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Sometimes bigger isn’t better; Noven says that the small size of its transdermal patch may be impetus for success.
You may also be interested in...
Berlex Climara Pro Gains Osteoporosis Prevention Indication
Berlex also updates labeling for the hormone replacement therapy to include new class labeling recommended by FDA.
NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue
FDA’s Arcoxia Decision Offers New Evidence Of Conservative Review Stance
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency